Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Healthcare Leader Exits, Bayer’s Pharma Business Quietly Thrives

This article was originally published in The Pink Sheet Daily

Executive Summary

While Bayer’s pharmaceutical business, tucked into an enormous conglomerate, sometimes flies under the radar of investors, it has had a strong year. The group that Jorg Reinhardt is leaving should continue to thrive, as it is buttressed by new product launches such as anti-coagulant Xarelto, a big presence in emerging markets, a full pipeline, and limited exposure to generic competition, analysts say.


Related Content

Bayer’s Reinhardt Returning To Novartis To Replace Departing Vasella


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts